Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kendra Sweet, Javier Pinilla-Ibarz & Ling Zhang. (2014) Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations. Patient Preference and Adherence 8, pages 981-986.
Read now
Read now
Articles from other publishers (14)
Carolina Alarcón-Payer, María Del Mar Sánchez Suárez, Alicia Martín Roldán, José Manuel Puerta Puerta & Alberto Jiménez Morales. (2022) Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia. Journal of Personalized Medicine 12:10, pages 1607.
Crossref
Crossref
Pranav Gupta, Yunali V. Ashar, Charles R. AshbyJr.Jr., Lusheng Lin & Zhe-Sheng Chen. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
312
328
.
Luca Mologni, Giovanni Marzaro, Sara Redaelli & Alfonso Zambon. (2021) Dual Kinase Targeting in Leukemia. Cancers 13:1, pages 119.
Crossref
Crossref
Naranie Shanmuganathan, Bradley Chereda & Junia V. Melo. 2021. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia
17
36
.
Vibhu Jha, Marco Macchia, Tiziano Tuccinardi & Giulio Poli. (2020) Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors. Cancers 12:8, pages 2327.
Crossref
Crossref
Carmen Segrelles, David Contreras, Elena Navarro, Carmen Gutiérrez-Muñoz, Ramón García-Escudero, Jesús Paramio & Corina Lorz. (2018) Bosutinib Inhibits EGFR Activation in Head and Neck Cancer. International Journal of Molecular Sciences 19:7, pages 1824.
Crossref
Crossref
Poe-Hirr Hsyu, Daniela Soriano Pignataro & Kyle Matschke. (2018) Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study. Clinical Pharmacology in Drug Development 7:4, pages 373-381.
Crossref
Crossref
Irina Sadovnik, Harald Herrmann, Gregor Eisenwort, Katharina Blatt, Gregor Hoermann, Niklas Mueller, Wolfgang R. Sperr & Peter Valent. (2017) Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications. Experimental Hematology 51, pages 17-24.
Crossref
Crossref
Pei San Yee, Chai Phei Gan, Nur Syafinaz Zainal, Ivy KN Chiang, Kalen R Dionne, Muhammad ZH Fadlullah, Bernard KB Lee, Kai Hung Tiong, Kein Seong Mun, Mannil T Abraham, Siti M Ismail, Zainal A Abdul Rahman, Vyomesh Patel & Sok Ching Cheong. (2017) Resistance to dasatinib is associated with the activation of Akt in oral squamous cell carcinoma. Translational Research in Oral Oncology 2, pages 2057178X1770292.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
415
434
.
Dawn M. Wetzel, Emma L. Rhodes, Shaoguang Li, Diane McMahon-Pratt & Anthony J. Koleske. (2016)
The Src kinases Hck, Fgr, and Lyn activate Abl2/Arg to facilitate IgG-mediated phagocytosis and
Leishmania
infection
. Journal of Cell Science.
Crossref
Crossref
Bradley Chereda & Junia V. Melo. 2016. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia
17
39
.
Carlo Gambacorti-Passerini, Andrea Aroldi, Nicoletta Cordani & Rocco Piazza. (2016) Chronic myeloid leukemia: Second-line drugs of choice. American Journal of Hematology 91:1, pages 67-75.
Crossref
Crossref
Linxia Wang, Luming Tang, Yi Zheng, Guoquan Pan, Wei Zhu, Chenwei Pan & Lihe Zhu. (2015) Determination of bosutinib in mice plasma and tissue by UPLC-MS/MS and its application to the pharmacokinetic and tissue distribution study. Analytical Methods 7:21, pages 9184-9189.
Crossref
Crossref